Citations (89)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Manoranjan Kerketta, Maruti Mali, Gattu Sridhar, Gangavaram V. M. Sharma & Jayaram Vankudoth. (2022) Synthesis of Tri-Substituted Olefin Derivatives from 1-Alkene-1,2-Diboronic Esters via Sequential Suzuki-Suzuki Coupling Reaction and Their Biological Activity. Polycyclic Aromatic Compounds 42:9, pages 6750-6759.
Read now
Read now
Yi-Min Liu, Hsiao-Ling Chen, Hsueh-Yun Lee & Jing-Ping Liou. (2014) Tubulin inhibitors: a patent review. Expert Opinion on Therapeutic Patents 24:1, pages 69-88.
Read now
Read now
Ming Kong, Jian Zhang, Cuihua Jiang, Xiao Jiang, Yue Li, Meng Gao, Nan Yao, Dejian Huang, Xiaoning Wang, Zhijun Fang, Wei Liu, Ziping Sun & Yicheng Ni. (2013) Necrosis affinity evaluation of 131I-hypericin in a rat model of induced necrosis. Journal of Drug Targeting 21:6, pages 604-610.
Read now
Read now
Monica M Mita, Liza Sargsyan, Alain C Mita & Matt Spear. (2013) Vascular-disrupting agents in oncology. Expert Opinion on Investigational Drugs 22:3, pages 317-328.
Read now
Read now
Articles from other publishers (85)
Sheo B. Singh. (2024) Discovery, synthesis, activities, structure–activity relationships, and clinical development of combretastatins and analogs as anticancer drugs. A comprehensive review. Natural Product Reports.
Crossref
Crossref
Juanjuan Yang, Dake Song, Bingqian Li, Xiaoxiao Gao, Yuetong Wang, Xiaohu Li, Changshun Bao, Caijiao Wu, Yu Bao, Samuel Waxman, Guoliang Chen & Yongkui Jing. (2023) Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance. Drug Resistance Updates 68, pages 100951.
Crossref
Crossref
Shannon N. Westin, Anil K. Sood & Robert L. Coleman. 2023. DiSaia and Creasman Clinical Gynecologic Oncology. DiSaia and Creasman Clinical Gynecologic Oncology
464
488.e11
.
Sevgi Gezici. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
34
.
Liliane Abodo Onambele, Natalie Hoffmann, Lisa Kater, Lars Hemmersbach, Jörg-Martin Neudörfl, Nikolay Sitnikov, Benjamin Kater, Corazon Frias, Hans-Günther Schmalz & Aram Prokop. (2022)
An organometallic analogue of combretastatin A-4 and its apoptosis-inducing effects on lymphoma, leukemia and other tumor cells
in vitro
. RSC Medicinal Chemistry 13:9, pages 1044-1051.
Crossref
Crossref
Yingyuan Peng, Zhixian Shi, Yuru Liang, Kuiling Ding & Yang Wang. (2022) Targeting the tumor microenvironment by an enzyme-responsive prodrug of tubulin destabilizer for triple-negative breast cancer therapy with high safety. European Journal of Medicinal Chemistry 236, pages 114344.
Crossref
Crossref
Faridah Ismail, Yusmazura Zakaria, Nik Fakhuruddin Nik Hassan & Muhammad Lokman Md Isa. (2022) Malaysian herbs as potential natural resources of anticancer drugs: From folklore to discovery. Asia Pacific Journal of Molecular Biology and Biotechnology, pages 62-89.
Crossref
Crossref
Sevgi Gezici. 2022. Herbal Bioactive-Based Drug Delivery Systems. Herbal Bioactive-Based Drug Delivery Systems
283
310
.
Hyehyun Jeong, Yong Sang Hong, Jeong Eun Kim, Hyeong-Seok Lim, Joong Bae Ahn, Sang Joon Shin, Young Suk Park, Seung Tae Kim, Sae-Won Han, Tae-You Kim & Tae Won Kim. (2021) A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. Investigational New Drugs 39:5, pages 1335-1347.
Crossref
Crossref
Bin Wang, Li-Ren Wang, Lu-Lu Liu, Wei Wang, Ruo-Jun Man, Da-Jun Zheng, Yu-Shan Deng, Yu-Shun Yang, Chen Xu & Hai-Liang Zhu. (2021) A novel series of benzothiazepine derivatives as tubulin polymerization inhibitors with anti-tumor potency. Bioorganic Chemistry 108, pages 104585.
Crossref
Crossref
Olagoke Zacchaeus Olatunde, Jianping Yong & Canzhong Lu. (2021) The Progress of the Anticancer Agents Related to the Microtubules Target. Mini-Reviews in Medicinal Chemistry 20:20, pages 2165-2192.
Crossref
Crossref
Ian Edwin Cock & Matthew Cheesman. 2021. Cancer. Cancer
495
503
.
Tushar Dubey, Nalini Vijay Gorantla, Kagepura Thammaiah Chandrashekara & Subashchandrabose Chinnathambi. (2020) Photodynamic exposure of Rose-Bengal inhibits Tau aggregation and modulates cytoskeletal network in neuronal cells. Scientific Reports 10:1.
Crossref
Crossref
Mai F. Tolba. (2020) Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors. International Journal of Cancer 147:11, pages 2996-3006.
Crossref
Crossref
Paola Oliva, Romeo Romagnoli, Stefano Manfredini, Andrea Brancale, Salvatore Ferla, Ernest Hamel, Roberto Ronca, Federica Maccarinelli, Arianna Giacomini, Fatlum Rruga, Elena Mariotto, Giampietro Viola & Roberta Bortolozzi. (2020) Design, synthesis, in vitro and in vivo biological evaluation of 2-amino-3-aroylbenzo[b]furan derivatives as highly potent tubulin polymerization inhibitors. European Journal of Medicinal Chemistry 200, pages 112448.
Crossref
Crossref
Andrii Malashchuk, Anton V. Chernykh, Vasyl V. Hurmach, Maxim O. Platonov, Oleksandra Onopchenko, Sergey Zozulya, Constantin G. Daniliuc, Alexey V. Dobrydnev, Ivan S. Kondratov, Yuriy S. Moroz & Oleksandr O. Grygorenko. (2020) Synthesis, biological evaluation, and modeling studies of 1,3-disubstituted cyclobutane-containing analogs of combretastatin A4. Journal of Molecular Structure 1210, pages 128025.
Crossref
Crossref
Yonghua Liu, Yanbin Wu, lianqi Sun, Yuxi Gu & Laixing Hu. (2020) Synthesis and structure-activity relationship study of water-soluble carbazole sulfonamide derivatives as new anticancer agents. European Journal of Medicinal Chemistry 191, pages 112181.
Crossref
Crossref
Sevgi Gezici & Nazım Şekeroğlu. (2019) Current Perspectives in the Application of Medicinal Plants Against Cancer: Novel Therapeutic Agents. Anti-Cancer Agents in Medicinal Chemistry 19:1, pages 101-111.
Crossref
Crossref
Brandon Bumbaca & Wei Li. (2018) Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies. Acta Pharmaceutica Sinica B 8:4, pages 518-529.
Crossref
Crossref
Khalid El Bairi, Mariam Amrani & Said Afqir. (2018) Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers. Cancer Medicine 7:6, pages 2221-2246.
Crossref
Crossref
Qiaomei Jin, Xin Shan, Qi Luo, Dongjian Zhang, Yuanyu Zhao, Nan Yao, Fei Peng, Dejian Huang, Zhiqi Yin, Wei Liu & Jian Zhang. (2018) 131I-Evans blue: evaluation of necrosis targeting property and preliminary assessment of the mechanism in animal models. Acta Pharmaceutica Sinica B 8:3, pages 390-400.
Crossref
Crossref
Makoto Nishio, Miyako Satouchi, Atsushi Horiike, Yoshitsugu Horio, Yoshinori Sunaga, Evelyne Ecstein-Fraisse & Toyoaki Hida. (2018) Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors. Japanese Journal of Clinical Oncology 48:4, pages 322-328.
Crossref
Crossref
Laura Conesa-Milián, Eva Falomir, Juan Murga, Miguel Carda, Eef Meyen, Sandra Liekens & J. Alberto Marco. (2018) Synthesis and biological evaluation of carbamates derived from aminocombretastatin A-4 as vascular disrupting agents. European Journal of Medicinal Chemistry 147, pages 183-193.
Crossref
Crossref
Shannon N. Westin, Anil K. Sood & Robert L. Coleman. 2018. Clinical Gynecologic Oncology. Clinical Gynecologic Oncology
470
492.e10
.
Syed Nasir Abbas Bukhari, Gajjela Bharath Kumar, Hrishikesh Mohan Revankar & Hua-Li Qin. (2017) Development of combretastatins as potent tubulin polymerization inhibitors. Bioorganic Chemistry 72, pages 130-147.
Crossref
Crossref
Fabián E. Olazaran, Gildardo Rivera, Alondra M. Pérez-Vázquez, Cynthia M. Morales-Reyes, Aldo Segura-Cabrera & Isaías Balderas-Rentería. (2016)
Biological Evaluation
in Vitro
and
in Silico
of Azetidin-2-one Derivatives as Potential Anticancer Agents
. ACS Medicinal Chemistry Letters 8:1, pages 32-37.
Crossref
Crossref
Zaki S. Seddigi, M. Shaheer Malik, A Prasanth Saraswati, Saleh A. Ahmed, Ahmed O. Babalghith, Hawazen A. Lamfon & Ahmed Kamal. (2017) Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents. MedChemComm 8:8, pages 1592-1603.
Crossref
Crossref
Jayabalan Shilpha, Lakkakula Satish & Manikandan Ramesh. 2017. Anticancer Plants: Clinical Trials and Nanotechnology. Anticancer Plants: Clinical Trials and Nanotechnology
233
252
.
Shunji Takahashi, Kenji Nakano, Tomoya Yokota, Kohei Shitara, Kei Muro, Yoshinori Sunaga, Evelyne Ecstein-Fraisse & Takashi Ura. (2016) Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors. Japanese Journal of Clinical Oncology 46:11, pages 1000-1007.
Crossref
Crossref
Mengqi Dong, Fang Liu, Hongyu Zhou, Shumei Zhai & Bing Yan. (2016) Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site. Molecules 21:10, pages 1375.
Crossref
Crossref
Mariana S. Gerova, Silviya R. Stateva, Elena M. Radonova, Rositsa B. Kalenderska, Rusi I. Rusew, Rositsa P. Nikolova, Christo D. Chanev, Boris L. Shivachev, Margarita D. Apostolova & Ognyan I. Petrov. (2016) Combretastatin A-4 analogues with benzoxazolone scaffold: Synthesis, structure and biological activity. European Journal of Medicinal Chemistry 120, pages 121-133.
Crossref
Crossref
Laxman Devkota, Chen-Ming Lin, Tracy E. Strecker, Yifan Wang, Justin K. Tidmore, Zhi Chen, Rajsekhar Guddneppanavar, Christopher J. Jelinek, Ramona Lopez, Li Liu, Ernest Hamel, Ralph P. Mason, David J. Chaplin, Mary Lynn Trawick & Kevin G. Pinney. (2016) Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents. Bioorganic & Medicinal Chemistry 24:5, pages 938-956.
Crossref
Crossref
Keita Takubo, Kazunori Furutsu, Takafumi Ide, Hiroyuki Nemoto, Yuko Ueda, Kazutake Tsujikawa, Takashi Ikawa, Takehiko Yoshimitsu & Shuji Akai. (2016) Diversity Oriented Synthesis of Allocolchicinoids with Fluoro and/or Oxygen Substituent(s) on the C‐Ring from a Single Common Intermediate. European Journal of Organic Chemistry 2016:8, pages 1562-1576.
Crossref
Crossref
Mariana S. Gerova, Gergina R. Encheva, Rositsa P. Nikolova, Christo D. Chanev, Boris L. Shivachev, Margarita D. Apostolova & Ognyan I. Petrov. (2016) Synthesis, Crystal Structure and Cytotoxic Properties of Nitrocombretastatins (E)- and (Z)-5-(4-Methoxy-3-nitrostyryl)-1,2,3-trimethoxybenzene. Journal of Chemical Crystallography 46:2, pages 105-112.
Crossref
Crossref
Yue Li, Cuihua Jiang, Xiao Jiang, Ziping Sun, Marlein Miranda Cona, Wei Liu, Jian Zhang & Yicheng Ni. (2015)
Biliary and duodenal drainage for reducing the radiotoxic risk of antineoplastic
131
I-hypericin in rat models
. Experimental Biology and Medicine 240:12, pages 1764-1773.
Crossref
Crossref
M. Kossai, B. Duchemann, C. Boutros, C. Caramella, A. Hollebecque, E. Angevin, A. Gazzah, R. Bahleda, E. Ileana, C. Massard, P. Vielh, J.C. Soria & B. Besse. (2015) Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer 89:3, pages 306-310.
Crossref
Crossref
Katharina Mahal, Bernhard Biersack, Henrike Caysa, Rainer Schobert & Thomas Mueller. (2015) Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation. Investigational New Drugs 33:3, pages 541-554.
Crossref
Crossref
Nan Yao, Meng Gao, Ke Ren, Xiao Jiang, Yue Li, Cuihua Jiang, Dejian Huang, Wei Liu, Xiaoning Wang, Zhijun Fang, Ziping Sun, Jian Zhang & Yicheng Ni. (2015) PD806. Anti-Cancer Drugs 26:2, pages 148-159.
Crossref
Crossref
Daniele Fanale, Giuseppe Bronte, Francesco Passiglia, Valentina Calò, Marta Castiglia, Florinda Di Piazza, Nadia Barraco, Antonina Cangemi, Maria Teresa Catarella, Lavinia Insalaco, Angela Listì, Rossella Maragliano, Daniela Massihnia, Alessandro Perez, Francesca Toia, Giuseppe Cicero & Viviana Bazan. (2015) Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?. Analytical Cellular Pathology 2015, pages 1-19.
Crossref
Crossref
Ahmed Kamal, A. V. Subba Rao, T. Srinivasa Reddy, Sowjanya Polepalli, Siddiq Pasha Shaik, Chandrakant Bagul, M. V. P. S. Vishnuvardhan & Nishant Jain. (2015) Aryl-imidazothiadiazole analogues as microtubule disrupting agents. MedChemComm 6:10, pages 1842-1856.
Crossref
Crossref
Ahmed Kamal, G. Bharath Kumar, Sowjanya Polepalli, Anver Basha Shaik, Vangala Santhosh Reddy, M. Kashi Reddy, Ch. Ratna Reddy, Rasala Mahesh, Jeevak Sopanrao Kapure & Nishant Jain. (2014) Design and Synthesis of Aminostilbene-Arylpropenones as Tubulin Polymerization Inhibitors. ChemMedChem 9:11, pages 2565-2579.
Crossref
Crossref
Ijin Joo, Jeong Min Lee, Joon Koo Han & Byung Ihn Choi. (2014) Intravoxel Incoherent Motion Diffusion-weighted MR Imaging for Monitoring the Therapeutic Efficacy of the Vascular Disrupting Agent CKD-516 in Rabbit VX2 Liver Tumors. Radiology 272:2, pages 417-426.
Crossref
Crossref
Yun Ji, Cuihua Jiang, Xueli Zhang, Wei Liu, Meng Gao, Yue Li, Junhu Wang, Qingqing Wang, Ziping Sun, Xiao Jiang, Nan Yao, Xiaoning Wang, Zhijun Fang, Zhiqi Yin, Yicheng Ni & Jian Zhang. (2014) Necrosis-targeted combinational theragnostic approach to treat cancer. Oncotarget 5:10, pages 2934-2946.
Crossref
Crossref
Chih-Yi Chang, Hsun-Yueh Chuang, Hsueh-Yun Lee, Teng-Kuang Yeh, Ching-Chuan Kuo, Chi-Yen Chang, Jang-Yang Chang & Jing-Ping Liou. (2014) Antimitotic and vascular disrupting agents: 2-Hydroxy-3,4,5-trimethoxybenzophenones. European Journal of Medicinal Chemistry 77, pages 306-314.
Crossref
Crossref
Katharina Mahal, Marcus Resch, Ralf Ficner, Rainer Schobert, Bernhard Biersack & Thomas Mueller. (2014) Effects of the Tumor-Vasculature-Disrupting Agent Verubulin and Two Heteroaryl Analogues on Cancer Cells, Endothelial Cells, and Blood Vessels. ChemMedChem 9:4, pages 847-854.
Crossref
Crossref
Verena K. Kretzschmann & Robert Fürst. (2013) Plant-derived vascular disrupting agents: compounds, actions, and clinical trials. Phytochemistry Reviews 13:1, pages 191-206.
Crossref
Crossref
H. Murakami, T. Kurata, Y. Onozawa, J. Watanabe, A. Ono, T. Takahashi, N. Yamamoto, Y. Fujisaka, H. Kiyota, H. Hayashi, K. Tanaka, K. Nakagawa & S. Kuroda. (2014) An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 73:3, pages 623-630.
Crossref
Crossref
Nitesh Sanghai, Vaibhav Jain, Ranjan Preet, Somnath Kandekar, Sarita Das, Neha Trivedi, Purusottam Mohapatra, Garima Priyadarshani, Maneesh Kashyap, Dipon Das, Shakti Ranjan Satapathy, Sumit Siddharth, Sankar K. Guchhait, Chanakya N. Kundu & Prasad V. Bharatam. (2014) Combretastatin A-4 inspired novel 2-aryl-3-arylamino-imidazo-pyridines/pyrazines as tubulin polymerization inhibitors, antimitotic and anticancer agents. Med. Chem. Commun. 5:6, pages 766-782.
Crossref
Crossref
Rajendra P. Tanpure, Clinton S. George, Tracy E. Strecker, Laxman Devkota, Justin K. Tidmore, Chen-Ming Lin, Christine A. Herdman, Matthew T. MacDonough, Madhavi Sriram, David J. Chaplin, Mary Lynn Trawick & Kevin G. Pinney. (2013) Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents. Bioorganic & Medicinal Chemistry 21:24, pages 8019-8032.
Crossref
Crossref
Kyung Won Kim, Jeong Min Lee, Yong Sik Jeon, In Joon Lee, YoonSeok Choi, Jisuk Park, Berthold Kiefer, Chin Kim, Joon Koo Han & Byung Ihn Choi. (2013) Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI. Investigational New Drugs 31:5, pages 1097-1106.
Crossref
Crossref
Cristiana Sessa, Patricia Lorusso, Anthony Tolcher, Françoise Farace, Nathalie Lassau, Angelo Delmonte, Antonio Braghetti, Rastislav Bahleda, Patrick Cohen, Marie Hospitel, Christine Veyrat-Follet & Jean-Charles Soria. (2013) Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors. Clinical Cancer Research 19:17, pages 4832-4842.
Crossref
Crossref
Edson dos A. dos Santos, Ernest Hamel, Ruoli Bai, James C. Burnett, Camila Santos Suniga Tozatti, Danielle Bogo, Renata T. Perdomo, Alexandra M.M. Antunes, M. Matilde Marques, Maria de F.C. Matos & Dênis P. de Lima. (2013) Synthesis and evaluation of diaryl sulfides and diaryl selenide compounds for antitubulin and cytotoxic activity. Bioorganic & Medicinal Chemistry Letters 23:16, pages 4669-4673.
Crossref
Crossref
N S Sitnikov & A Yu Fedorov. (2013) Synthesis of allocolchicinoids: a 50 year journey. Russian Chemical Reviews 82:5, pages 393-411.
Crossref
Crossref
Lisa Greene. (2013) Combretazet-3 a novel synthetic cis-stable combretastatin�A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer. Oncology Reports.
Crossref
Crossref
Céline Clémenson, Erwan Jouannot, Ana Merino-Trigo, Chantal Rubin-Carrez & Eric Deutsch. (2012) The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. Investigational New Drugs 31:2, pages 273-284.
Crossref
Crossref
Nancy Ty, Renée Pontikis, Guy G. Chabot, Emmanuelle Devillers, Lionel Quentin, Stéphane Bourg & Jean-Claude Florent. (2013) Synthesis and biological evaluation of enantiomerically pure cyclopropyl analogues of combretastatin A4. Bioorganic & Medicinal Chemistry 21:5, pages 1357-1366.
Crossref
Crossref
Renata Mikstacka, Tomasz Stefański & Jakub Różański. (2013) Tubulin-interactive stilbene derivatives as anticancer agents. Cellular and Molecular Biology Letters 18:3.
Crossref
Crossref
Yong Zou, Qi Huang, Tong-kun Huang, Qing-chun Ni, En-sheng Zhang, Tian-long Xu, Mu Yuan & Jun Li. (2013) CuI/1,10-phen/PEG promoted decarboxylation of 2,3-diarylacrylic acids: synthesis of stilbenes under neutral and microwave conditions with an in situ generated recyclable catalyst. Organic & Biomolecular Chemistry 11:40, pages 6967.
Crossref
Crossref
Vivien Stocker, Alina Ghinet, Marie Leman, Benoît Rigo, Régis Millet, Amaury Farce, Déborah Desravines, Joëlle Dubois, Christophe Waterlot & Philippe Gautret. (2013) On the synthesis and biological properties of isocombretastatins: a case of ketone homologation during Wittig reaction attempts. RSC Advances 3:11, pages 3683.
Crossref
Crossref
Jessy Aziz, Etienne Brachet, Abdallah Hamze, Jean-François Peyrat, Guillaume Bernadat, Estelle Morvan, Jérôme Bignon, Joanna Wdzieczak-Bakala, Déborah Desravines, Joelle Dubois, Marie Tueni, Ahmad Yassine, Jean-Daniel Brion & Mouad Alami. (2013) Synthesis, biological evaluation, and structure–activity relationships of tri- and tetrasubstituted olefins related to isocombretastatin A-4 as new tubulin inhibitors. Org. Biomol. Chem. 11:3, pages 430-442.
Crossref
Crossref
Tsai-Yuan Chang, Yun-Peng Tu, Win-Yin Wei, Hsiang Yu Chen, Chih-Shang Chen, Ying-Shuan E. Lee, Jiann-Jyh Huang & Chin-Kang Sha. (2012) Synthesis and Antiproliferative Activities of Ottelione A Analogues. ACS Medicinal Chemistry Letters 3:12, pages 1075-1080.
Crossref
Crossref
Thi Thanh Binh Nguyen, Thierry Lomberget, Ngoc Chau Tran, Evelyne Colomb, Lore Nachtergaele, Sylviane Thoret, Joëlle Dubois, Joren Guillaume, Rawad Abdayem, Marek Haftek & Roland Barret. (2012) Synthesis and biological evaluation of novel heterocyclic derivatives of combretastatin A-4. Bioorganic & Medicinal Chemistry Letters 22:23, pages 7227-7231.
Crossref
Crossref
Miguel A. González, David Pérez-Guaita, Lee S. Agudelo-Goméz, Verónica Tangarife-Castaño, Bibiana Zapata & Liliana Betancur-Galvis. (2019) Synthesis and Biological Evaluation of Combretastatin A-4 and Three Combretastatin-Based Hybrids. Natural Product Communications 7:8, pages 1934578X1200700.
Crossref
Crossref
John A. Hadfield, Nicholas Hirst, Keira Gaukroger, Nicholas J. Lawrence & Alan T. McGown. (2012) A practical radiosynthesis of a tritium-labelled fluorocombretastatin. Journal of Labelled Compounds and Radiopharmaceuticals 55:8, pages 303-306.
Crossref
Crossref
Jia Liu, Can-Hui Zheng, Xiao-Hui Ren, Feng Zhou, Wei Li, Ju Zhu, Jia-Guo Lv & You-Jun Zhou. (2012) Synthesis and Biological Evaluation of 1-Benzylidene-3,4-dihydronaphthalen-2-one as a New Class of Microtubule-Targeting Agents. Journal of Medicinal Chemistry 55:12, pages 5720-5733.
Crossref
Crossref
Jin Zhang, Jing Zhou, Xiaomei Ren, Yanyan Diao, Honglin Li, Hualiang Jiang, Ke Ding & Duanqing Pei. (2010) A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton. Investigational New Drugs 30:2, pages 490-507.
Crossref
Crossref
Desmond B. S. Pink, Wendy Schulte, Missag H. Parseghian, Andries Zijlstra & John D. Lewis. (2012) Real-Time Visualization and Quantitation of Vascular Permeability In Vivo: Implications for Drug Delivery. PLoS ONE 7:3, pages e33760.
Crossref
Crossref
Huaijun Wang, Marlein Miranda Cona, Feng Chen, Jie Yu, Yuanbo Feng, Junjie Li, Frederik De Keyzer, Guy Marchal & Yicheng Ni. (2012) Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers. Anti-Cancer Drugs 23:1, pages 12-21.
Crossref
Crossref
Shridhar Bhat, Joong Sup Shim, Feiran Zhang, Curtis Robert Chong & Jun O. Liu. (2012) Substituted oxines inhibit endothelial cell proliferation and angiogenesis. Organic & Biomolecular Chemistry 10:15, pages 2979.
Crossref
Crossref
Shannon N. Westin, Anil K. Sood & Robert L. Coleman. 2012. Clinical Gynecologic Oncology. Clinical Gynecologic Oncology
539
560.e6
.
Hsueh-Yun Lee, Jang-Yang Chang, Chih-Ying Nien, Ching-Chuan Kuo, Kuang-Hsing Shih, Chun-Hsein Wu, Chi-Yen Chang, Wen-Yang Lai & Jing-Ping Liou. (2011) 5-Amino-2-aroylquinolines as Highly Potent Tubulin Polymerization Inhibitors. Part 2. The Impact of Bridging Groups at Position C-2. Journal of Medicinal Chemistry 54:24, pages 8517-8525.
Crossref
Crossref
Xian-hua Fu, Jun Li, Yong Zou, Yu-rong Hong, Zhi-xuan Fu, Jian-jin Huang, Su-zhan Zhang & Shu Zheng. (2011) Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft. Cancer Letters 312:1, pages 109-116.
Crossref
Crossref
Bernhard Biersack, Yazh Muthukumar, Rainer Schobert & Florenz Sasse. (2011) Cytotoxic and antivascular 1-methyl-4-(3-fluoro-4-methoxyphenyl)-5-(halophenyl)-imidazoles. Bioorganic & Medicinal Chemistry Letters 21:21, pages 6270-6273.
Crossref
Crossref
David Cragg, Gordon Kingston & David NewmanKevin Pinney, George Pettit, Mary Trawick, Christopher Jelinek & David Chaplin. 2011. Anticancer Agents from Natural Products, Second Edition. Anticancer Agents from Natural Products, Second Edition
27
64
.
Romeo Romagnoli, Pier Giovanni Baraldi, Carlota Lopez-Cara, Olga Cruz-Lopez, Maria Dora Carrion, Maria Kimatrai Salvador, Jaime Bermejo, Sara Estévez, Francisco Estévez, Jan Balzarini, Andrea Brancale, Antonio Ricci, Longchuan Chen, Jae Gwan Kim & Ernest Hamel. (2011) Synthesis and Antitumor Molecular Mechanism of Agents Based on Amino 2-(3′,4′,5′-Trimethoxybenzoyl)benzo[b]furan: Inhibition of Tubulin and Induction of Apoptosis. ChemMedChem 6:10, pages 1841-1853.
Crossref
Crossref
Junjie Li, Ziping Sun, Jian Zhang, Haibo Shao, Marlein Miranda Cona, Huaijun Wang, Thierry Marysael, Feng Chen, Kristof Prinsen, Lin Zhou, Dejian Huang, Johan Nuyts, Jie Yu, Bin Meng, Guy Bormans, Zhijun Fang, Peter de Witte, Yaming Li, Alfons Verbruggen, Xiaoning Wang, Luc Mortelmans, Ke Xu, Guy Marchal & Yicheng Ni. (2011) A Dual-targeting Anticancer Approach: Soil and Seed Principle. Radiology 260:3, pages 799-807.
Crossref
Crossref
Baojian Wu, Kaustubh Kulkarni, Sumit Basu, Shuxing Zhang & Ming Hu. (2011) First-Pass Metabolism via UDP-Glucuronosyltransferase: a Barrier to Oral Bioavailability of Phenolics. Journal of Pharmaceutical Sciences 100:9, pages 3655-3681.
Crossref
Crossref
Ishwaria M. SubbiahDaniel J. LenihanApostolia M. Tsimberidou. (2011) Cardiovascular Toxicity Profiles of Vascular-Disrupting Agents. The Oncologist 16:8, pages 1120-1130.
Crossref
Crossref
Sewan Theeramunkong, Antonio Caldarelli, Alberto Massarotti, Silvio Aprile, Diego Caprioglio, Roberta Zaninetti, Alessia Teruggi, Tracey Pirali, Giorgio Grosa, Gian Cesare Tron & Armando A. Genazzani. (2011) Regioselective Suzuki Coupling of Dihaloheteroaromatic Compounds as a Rapid Strategy To Synthesize Potent Rigid Combretastatin Analogues. Journal of Medicinal Chemistry 54:14, pages 4977-4986.
Crossref
Crossref
Sébastien Fortin, Lianhu Wei, Emmanuel Moreau, Jacques Lacroix, Marie-France Côté, Éric Petitclerc, Lakshmi P. Kotra & René C.-Gaudreault. (2011) Design, Synthesis, Biological Evaluation, and Structure–Activity Relationships of Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl)benzenesulfonates as New Tubulin Inhibitors Mimicking Combretastatin A-4. Journal of Medicinal Chemistry 54:13, pages 4559-4580.
Crossref
Crossref
Arman Hasani & Natasha Leighl. (2011) Classification and Toxicities of Vascular Disrupting Agents. Clinical Lung Cancer 12:1, pages 18-25.
Crossref
Crossref
Ralph P. Mason, Dawen Zhao, Li Liu, Mary Lynn Trawick & Kevin G. Pinney. (2011) A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integrative Biology 3:4, pages 375.
Crossref
Crossref
David J. Edwards, John A. Hadfield, Timothy W. Wallace & Sylvie Ducki. (2011) Tubulin-binding dibenz[c,e]oxepines as colchinol analogues for targeting tumour vasculature. Org. Biomol. Chem. 9:1, pages 219-231.
Crossref
Crossref
Charles Dumontet & Mary Ann Jordan. (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nature Reviews Drug Discovery 9:10, pages 790-803.
Crossref
Crossref
Li Pan, Heebyung Chai & A. Douglas Kinghorn. (2010) The continuing search for antitumor agents from higher plants. Phytochemistry Letters 3:1, pages 1-8.
Crossref
Crossref